PL2219452T3 - Sposoby leczenia twardziny - Google Patents

Sposoby leczenia twardziny

Info

Publication number
PL2219452T3
PL2219452T3 PL08847680T PL08847680T PL2219452T3 PL 2219452 T3 PL2219452 T3 PL 2219452T3 PL 08847680 T PL08847680 T PL 08847680T PL 08847680 T PL08847680 T PL 08847680T PL 2219452 T3 PL2219452 T3 PL 2219452T3
Authority
PL
Poland
Prior art keywords
methods
treating scleroderma
scleroderma
treating
Prior art date
Application number
PL08847680T
Other languages
English (en)
Inventor
Anthony Coyle
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of PL2219452T3 publication Critical patent/PL2219452T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
PL08847680T 2007-11-05 2008-11-05 Sposoby leczenia twardziny PL2219452T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99617507P 2007-11-05 2007-11-05
US10045408P 2008-09-26 2008-09-26
EP08847680.9A EP2219452B1 (en) 2007-11-05 2008-11-05 Methods of treating scleroderma
PCT/US2008/082481 WO2009061818A1 (en) 2007-11-05 2008-11-05 Methods of treating scleroderma

Publications (1)

Publication Number Publication Date
PL2219452T3 true PL2219452T3 (pl) 2016-04-29

Family

ID=43087976

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08847680T PL2219452T3 (pl) 2007-11-05 2008-11-05 Sposoby leczenia twardziny

Country Status (21)

Country Link
US (1) US20110008365A1 (pl)
EP (1) EP2219452B1 (pl)
JP (2) JP5767475B2 (pl)
KR (1) KR20100098620A (pl)
CN (1) CN101909444B (pl)
AU (1) AU2008324800B2 (pl)
BR (1) BRPI0819195A2 (pl)
CA (1) CA2703705A1 (pl)
CY (1) CY1117251T1 (pl)
DK (1) DK2219452T3 (pl)
ES (1) ES2557352T3 (pl)
HR (1) HRP20151403T1 (pl)
HU (1) HUE025787T2 (pl)
IL (1) IL205452A (pl)
MX (1) MX2010004814A (pl)
NZ (1) NZ585064A (pl)
PL (1) PL2219452T3 (pl)
PT (1) PT2219452E (pl)
RU (1) RU2530561C2 (pl)
SI (1) SI2219452T1 (pl)
WO (1) WO2009061818A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2250279T3 (pl) 2008-02-08 2016-11-30 Przeciwciała anty-ifnar1 o zmniejszonym powinowactwie do liganda fc
CA2836926A1 (en) * 2011-05-25 2012-11-29 Medimmune, Llc Methods of treating systemic lupus erythematosus, scleroderma, and myositis with an antibody against interferon-alpha
JP2015526391A (ja) * 2012-06-13 2015-09-10 メディミューン，エルエルシー 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン
CN108603885A (zh) * 2015-11-17 2018-09-28 科罗拉多大学评议会公司 诊断或评估哺乳动物中的疾病或紊乱的新型多重分析
MX2023012465A (es) 2021-04-23 2024-04-04 Astrazeneca Ab Regimen de dosificacion de anti-ifnar1 para inyeccion subcutanea.
CN118320101B (zh) * 2024-06-14 2024-09-17 天津嘉氏堂科技有限公司 iNOS抑制剂在制备治疗硬皮病胶原沉积药物中的应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3461808A (en) 1967-07-03 1969-08-19 Wood John Co Diaphragm hand pumps
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8303165D0 (en) 1983-02-04 1983-03-09 Secher D S Monoclonal antibody
WO1984003106A1 (en) 1983-02-04 1984-08-16 Wadley Inst Of Molecular Medic Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins
DE3306060A1 (de) 1983-02-22 1984-08-23 Boehringer Ingelheim International GmbH, 6507 Ingelheim Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
EP0205404B1 (en) 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid interferons
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3923126A1 (de) 1989-07-13 1991-01-17 Stark Henric Lautsprecherbox
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US4997008A (en) 1990-04-26 1991-03-05 Moen Incorporated Faucet spout assembly
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
EP1471142B1 (en) 1991-04-10 2008-11-19 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
AU696293B2 (en) 1993-12-08 1998-09-03 Genzyme Corporation Process for generating specific antibodies
DK0744958T3 (da) 1994-01-31 2003-10-20 Univ Boston Polyklonale antistofbiblioteker
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US7285526B2 (en) * 1995-07-14 2007-10-23 Meiogen Biotechnology Corporation Interferon antagonists useful for the treatment of interferon related diseases
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6713609B1 (en) 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
CN100387621C (zh) 1997-04-14 2008-05-14 麦可麦脱股份公司 抗人抗原受体的新的生产方法及其用途
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6311415B1 (en) 1998-09-14 2001-11-06 Lind Shoe Company Bowling shoe with replaceable tip
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
US7858095B2 (en) * 2001-07-24 2010-12-28 Astellas Us Llc Method for treating or preventing sclerotic disorders using CD-2 binding agents
AU2002324727A1 (en) * 2001-08-17 2003-03-03 The Board Of Trustees Of The Leland Stanford Junior University Mammalian relaxin receptors
CN100374457C (zh) * 2001-11-14 2008-03-12 森托科尔公司 抗il-6抗体、组合物、方法和用途
KR101151477B1 (ko) 2003-12-10 2012-06-22 메다렉스, 인코포레이티드 인터페론 알파 항체 및 그의 용도
WO2005067963A1 (en) * 2003-12-23 2005-07-28 Intermune, Inc. Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
JP5160887B2 (ja) * 2004-06-21 2013-03-13 メダレックス インコーポレイテッド インターフェロンアルファレセプター１抗体及びその使用法
US20070081995A1 (en) * 2005-06-22 2007-04-12 Genentech, Inc. Methods and compositions for targeting IFNAR2
EP1945800B1 (en) * 2005-08-05 2012-03-14 Genentech, Inc. Methods and compositions for detecting autoimmune disorders
RU2527068C2 (ru) 2006-12-06 2014-08-27 Медиммун, Ллк Фармакодинамические маркеры, индуцированные интерфероном альфа

Also Published As

Publication number Publication date
AU2008324800B2 (en) 2014-03-27
JP2014144966A (ja) 2014-08-14
HRP20151403T1 (hr) 2016-02-12
JP5767475B2 (ja) 2015-08-19
JP2011503008A (ja) 2011-01-27
EP2219452A4 (en) 2012-05-02
RU2530561C2 (ru) 2014-10-10
SI2219452T1 (sl) 2016-03-31
DK2219452T3 (en) 2016-01-11
MX2010004814A (es) 2010-08-10
RU2010122644A (ru) 2011-12-20
US20110008365A1 (en) 2011-01-13
WO2009061818A1 (en) 2009-05-14
AU2008324800A1 (en) 2009-05-14
KR20100098620A (ko) 2010-09-08
ES2557352T3 (es) 2016-01-25
BRPI0819195A2 (pt) 2017-05-23
CN101909444B (zh) 2013-09-18
IL205452A0 (en) 2010-12-30
HUE025787T2 (en) 2016-05-30
CN101909444A (zh) 2010-12-08
HK1151190A1 (zh) 2012-04-05
CA2703705A1 (en) 2009-05-14
NZ585064A (en) 2012-08-31
PT2219452E (pt) 2016-01-26
CY1117251T1 (el) 2017-04-26
EP2219452B1 (en) 2015-10-14
IL205452A (en) 2016-02-29
EP2219452A1 (en) 2010-08-25

Similar Documents

Publication Publication Date Title
IL257418A (en) Methods for treating addiction
IL207752A0 (en) Methods of treating inflammation
ZA201006648B (en) Methods of treatment
EP2331564A4 (en) PROCESS FOR TREATMENT OF IGNITION
GB2454797B (en) Treatment of wastewater
ZA201006070B (en) Methods of treating inflammatory pain
GB2475018B (en) Water treatment methods
GB0802116D0 (en) Treatment
IL227641A0 (en) Methods for treating arthritis
IL210097A0 (en) Compositions and methods for treating unfluenza
EP2350641A4 (en) Methods of Treatment
ZA200907349B (en) Method of treating hair
GB0811992D0 (en) Treatment
IL205452A0 (en) Methods of treating scleroderma
EP2144886A4 (en) METHOD OF TREATING MELANOMA
GB0708452D0 (en) Treatment of nuclear studge
EP2164494A4 (en) Methods of Treatment
GB0723100D0 (en) Treatment of HFnEF
ZA201007680B (en) Method of treating metalliferrous materials
GB0805912D0 (en) Treatment
EP2203432A4 (en) PROCESSING METHOD
ZA201100490B (en) Treatment of thrombocytopenia
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia
GB0700969D0 (en) Methods of treatment
ZA201006046B (en) Methods of treating inflammation